​

Viridian Therapeutics (VRDN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VRDN Stock Forecast

Viridian Therapeutics (VRDN) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $36.86, with a high of $50.00 and a low of $26.00. This represents a 128.38% increase from the last price of $16.14.

$10 $18 $26 $34 $42 $50 High: $50 Avg: $36.86 Low: $26 Last Closed Price: $16.14

VRDN Stock Rating

Viridian Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (81.25%), 3 Hold (18.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 3 13 Strong Sell Sell Hold Buy Strong Buy

VRDN Price Target Upside V Benchmarks

TypeNameUpside
StockViridian Therapeutics128.38%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2617
Avg Price Target$32.50$33.17$39.65
Last Closing Price$16.14$16.14$16.14
Upside/Downside101.36%105.51%145.66%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 263131--17
May, 263131--17
Apr, 263141--18
Mar, 263141--18
Feb, 263141--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2026Evercore ISI$26.00$16.8654.21%61.09%
May 13, 2026Stifel Nicolaus$39.00$16.77132.56%141.64%
May 06, 2026RBC Capital$34.00$18.7581.33%110.66%
Apr 21, 2026Truist Financial$33.00$14.50127.59%104.46%
Apr 08, 2026Truist Financial$36.00$14.47148.79%123.05%
Apr 08, 2026Laura ChicoWedbush$31.00$14.47114.24%92.07%
Feb 26, 2026Kelly ShiJefferies$45.00$28.8056.25%178.81%
Jan 28, 2026Gavin Clark-GartnerEvercore ISI$45.00$33.1435.79%178.81%
Jan 20, 2026Gavin Clark-GartnerEvercore ISI$44.00$32.6334.85%172.61%
Jan 07, 2026UBS$50.00$30.8262.23%209.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 06, 2026RBC CapitalOutperformOutperformhold
Apr 08, 2026WedbushOutperformOutperformhold
Feb 26, 2026JefferiesBuyBuyhold
Feb 26, 2026Evercore ISIOutperformOutperformhold
Jan 20, 2026Evercore ISIOutperformOutperformhold
Jan 07, 2026UBSBuyinitialise
Jan 06, 2026Cowen & Co.BuyBuyhold
Jan 06, 2026JefferiesBuyBuyhold
Dec 18, 2025Goldman SachsBuyBuyhold
Dec 03, 2025William BlairOutperforminitialise

Financial Forecast

EPS Forecast

$-250 $-190 $-130 $-70 $-10 $50 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.66$-3.91$-5.31$-3.98$-221.65---
Avg Forecast$-5.38$-3.56$-4.94$-4.03$-4.16$-4.21$-1.53$1.37
High Forecast$-1.14$-1.61$-4.63$-3.85$-3.61$-2.35$3.81$2.84
Low Forecast$-14.20$-9.63$-5.48$-4.17$-4.67$-6.61$-4.08$0.56
Surprise %23.79%9.83%7.49%-1.24%5228.13%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.96M$1.77M$314.00K$302.00K$70.85M---
Avg Forecast$3.00M$2.13M$373.08K$317.29K$239.29K$45.91M$333.37M$667.21M
High Forecast$6.78M$4.92M$830.41K$411.30K$435.06K$48.18M$333.37M$1.21B
Low Forecast$1.18M$1.23M$240.70K$235.03K$130.52K$43.63M$333.37M$363.93M
Surprise %-1.30%-16.72%-15.84%-4.82%29508.50%---

Net Income Forecast

$-650M $-480M $-310M $-140M $30M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-79.41M$-129.87M$-237.73M$-269.95M$-342.60M---
Avg Forecast$-240.98M$-159.21M$-237.73M$-179.56M$-185.24M$-200.63M$-134.61M$61.50M
High Forecast$-51.21M$-71.93M$-207.35M$-172.40M$-161.68M$-105.31M$170.56M$126.91M
Low Forecast$-635.58M$-431.02M$-245.13M$-186.72M$-208.80M$-295.96M$-182.64M$25.16M
Surprise %-67.05%-18.43%-50.34%84.95%---

VRDN Forecast FAQ

Is Viridian Therapeutics stock a buy?

Viridian Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Viridian Therapeutics is a favorable investment for most analysts.

What is Viridian Therapeutics's price target?

Viridian Therapeutics's price target, set by 16 Wall Street analysts, averages $36.86 over the next 12 months. The price target range spans from $26 at the low end to $50 at the high end, suggesting a potential 128.38% change from the previous closing price of $16.14.

How does Viridian Therapeutics stock forecast compare to its benchmarks?

Viridian Therapeutics's stock forecast shows a 128.38% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Viridian Therapeutics over the past three months?

  • June 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 16.67% Strong Buy, 77.78% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.

What is Viridian Therapeutics’s EPS forecast?

Viridian Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.21, marking a -98.10% decrease from the reported $-222 in 2025. Estimates for the following years are $-1.53 in 2027, and $1.37 in 2028.

What is Viridian Therapeutics’s revenue forecast?

Viridian Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $45.91M, reflecting a -35.20% decrease from the reported $70.85M in 2025. The forecast for 2027 is $333.37M, and $667.21M for 2028.

What is Viridian Therapeutics’s net income forecast?

Viridian Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-201M, representing a -41.44% decrease from the reported $-343M in 2025. Projections indicate $-135M in 2027, and $61.5M in 2028.